Vnitr Lek 2024, 70(1):7-12 | DOI: 10.36290/vnl.2024.001

Pituitary adenomas from the internist's perspective

Jana Ježková, Tomáš Brutvan
3. interní klinika 1. LF UK a VFN, Praha

Pituitary adenomas are the most common tumours of the sellar region. Prolactinomas are the most common type, followed by clinically non-functioning pituitary adenomas, acromegaly (Growth-Hormone secreting pituitary adenoma) and Cushing's disease (ACTH-secreting pituitary adenoma). Thyrotropinomas (TSH-secreting pituitary adenoma) and functional gonadotropinomas are rare. The correct diagnosis is based on the manifestation of clinical symptoms, evaluation of laboratory test results including dynamic tests, and imaging findings - most commonly Magnetic Resonance Imaging. Treatment of pituitary adenomas is often complex and involves a combination of treatment modalities: neurosurgery, medical therapy and radiotherapy. In most cases, neurosurgery is the treatment of choice. The exception is prolactinomas, for which the primary treatment is medical therapy with dopaminergic agonists.

Keywords: pituitary adenoma, prolactinoma, acromegaly, Cushing's disease, hypopituitarismus.

Accepted: February 9, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ježková J, Brutvan T. Pituitary adenomas from the internist's perspective. Vnitr Lek. 2024;70(1):7-12. doi: 10.36290/vnl.2024.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021;23(suppl3):1-105. Go to original source... Go to PubMed...
    2. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;10 (3):613-9. Go to original source... Go to PubMed...
    3. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study on the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-75. Go to original source... Go to PubMed...
    4. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a comminity-based, cross-sectinal study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377-82. Go to original source... Go to PubMed...
    5. Briet C, Salenave S, Bonneville JF, et al. Pituitary apoplexy. Endocr Rev. 2015;36(6):622-45. Go to original source... Go to PubMed...
    6. Molitch ME. Pituitary tumours: pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):667-75. Go to original source... Go to PubMed...
    7. Almutairi RD, Muskens IS, Cote DJ, et al. Gross Total Resection of Pituitary Adenomas after Endoscopic vs. Microscopic Transsphenoidal Surgery: A meta analysis. Acta Neurochir. 2018;160(5):1005-21. Go to original source... Go to PubMed...
    8. Delgrange E, Daems T, Verhelst J, et al. Characterization of resistence to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747-752. Go to original source... Go to PubMed...
    9. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med. 1994;331(14):904-909. Go to original source... Go to PubMed...
    10. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-152. Go to original source... Go to PubMed...
    11. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008; 159(2):89-95. Go to original source... Go to PubMed...
    12. Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561. Go to original source... Go to PubMed...
    13. Giustina A, Chanson P, Bronstein MD, et al. Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010; Jul;95(7):3141-8. Go to original source... Go to PubMed...
    14. Jane jr. JA, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications and predictors of outcome. J Clin Endocrinol Metab. 2011;96(9):2732-2740. Go to original source... Go to PubMed...
    15. Starke RM, Raper DM, Payne SC, et al. Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab. 2013;98(8):3190-3198. Go to original source... Go to PubMed...
    16. Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkagewith lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014;99(4):1282-1290. Go to original source... Go to PubMed...
    17. Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411. Go to original source... Go to PubMed...
    18. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on convenctional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161(2):331-338. Go to original source... Go to PubMed...
    19. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156(1): 75-82. Go to original source... Go to PubMed...
    20. Ferrau F, and Korbonits M. Metabolic comorbidities in Cushing's syndrome. Eur J Endocrinol. 2015;173(4):M133-157. doi: 10.1530/EJE-15-0354. Go to original source... Go to PubMed...
    21. Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing's disease. Endocr Rev. 2015;36(4):385-486. Go to original source... Go to PubMed...
    22. Marek M, Jezkova J, Hana V, et al. Gamma knife radiosurgery for Cushing's disease and Nelson's syndrome. Pituitary. 2015;18 (3)376-384 Go to original source... Go to PubMed...
    23. Kazlauskaite R, Evans ATm Villabona CV, et al. Corticotropin test for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008; 93:4245-4253. Go to original source... Go to PubMed...
    24. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal gland disease. J Clin Endocrinol Metab. 2003;88:4193-8. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.